Empyrean, MagCorp, and MetOx Announce Strategic Collaboration Agreement on the Scale-up of Novel Technology for Radiation Therapy and Cancer Treatment
BOCA RATON, Fla., Aug. 28, 2023 /PRNewswire/ -- Empyrean Medical Systems, Inc. ("Empyrean"), MagCorp Inc. ("MagCorp"), and MetOx Technologies, Inc. ("MetOx") today announced a strategic collaboration agreement to accelerate the large-scale development of novel technology that will enable commercial production of next generation, state-of-the-art radiation therapy technology for cancer treatment.
- BOCA RATON, Fla., Aug. 28, 2023 /PRNewswire/ -- Empyrean Medical Systems, Inc. ("Empyrean"), MagCorp Inc. ("MagCorp"), and MetOx Technologies, Inc. ("MetOx") today announced a strategic collaboration agreement to accelerate the large-scale development of novel technology that will enable commercial production of next generation, state-of-the-art radiation therapy technology for cancer treatment.
- The success of this manufacturing collaboration will have a dramatic impact on the future of oncology and will unlock the potential of this technology to serve the rapidly growing global need for novel cancer treatment technology.
- "After commercially launching the Morpheus™ system this year, we are entering our next phases of innovation and critical technology development.
- "Only HTS can enable the high magnetic fields required for this exciting technology, and we're thrilled to partner with Empyrean and MagCorp on this life-saving initiative."